Novo Nordisk CEO to Exit Amid Market Challenges
After more than three decades with Novo Nordisk and eight years leading the Danish pharmaceutical manufacturer, Lars Fruergaard Jørgensen will step down as Chief Executive.
His exit comes at a time when the company faces falling share prices, missed forecasts and scrutiny from the Novo Nordisk Foundation.
The company confirms Lars will remain in his role until a successor is appointed.
His exit arrives just days after the firm lowered its sales and profit projections for the first time since launching Wegovy, its weight-loss injection, in 2021.
Forecast cuts and market value loss
Wegovy once led the obesity drug market but now trails behind Zepbound, a rival injectable from Eli Lilly, in US prescription volumes. That shift in competitive standing contributes to Novo Nordisk’s market capitalisation being halved—from a $615bn peak in June 2024 to about $310bn.
The company acknowledged in a statement: “Considering the recent market challenges, the share price decline and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that initiating a CEO succession is in the best interest of the company and its shareholders.”
While such decisions often involve a mixture of performance assessment and strategic recalibration, Novo’s changing fortunes have created pressure from multiple angles—including the Foundation that holds controlling interest.
Production shortfalls and public health risks
One of the key challenges hitting Novo Nordisk is its challenges meeting soaring demand for its obesity and diabetes treatments, including Ozempic and Wegovy.
The supply chain has struggled to respond to off-label demand for low-dose Ozempic, commonly used for weight loss.
In Australia, Novo Nordisk formally advised both the Therapeutic Goods Administration and the Ozempic Medicine Shortage Action Group last year that shortages would continue.
According to the National Pharmacy Association, supply issues could potentially drive patients toward unregulated sources, with the risk of exposure to counterfeit products.
Michael Shah, a Senior Analyst at Bloomberg Intelligence, says: “Jorgensen’s surprise departure from Novo Nordisk corroborates the perception that the company has lost ground to Eli Lilly in the obesity space. This includes underwhelming results for CagriSema as well as supply chain constraints and market challenges for Wegovy.”
Leadership moves and strategic continuity
Novo Nordisk’s board Chair Helge Lund maintains that the company’s strategy will remain unchanged, as reported by Reuters, despite the high-profile leadership change.
He revealed that discussions about succession have been underway for several weeks.
Alongside Lars’s planned exit, another executive departure underlines the internal shift. Camilla Sylvest, previously Executive Vice President of Commercial Strategy and regarded as a close associate of Lars, left her post last month.
Lars has described the decision as unexpected. Speaking to Danish broadcaster TV2, he says he was only told “very recently.”
Posting on LinkedIn, he reflected: “This is not an easy post to write – not because I’m unsure of what to say, but because there is simply so much I’m grateful for… It’s been the privilege of a lifetime.”
Explore the latest edition of Manufacturing Digital and be part of the conversation at our global conference series, Manufacturing LIVE.
Discover all our upcoming events and secure your tickets today.
Manufacturing Digital is a BizClik brand.
